letsasfen.blogg.se - august 2022

#Timi trials trial#

Ticagrelor may be preferable to clopidogrel for maintenance P2Y 12 inhibitor therapy (COR IIa, LOE B-R).If BMS or DES, treat with DAPT, including a P2Y 12 inhibitor (clopidogrel, prasugrel, or ticagrelor) for ≥12 mo (COR I, LOE B-R).If DES and high-risk for bleeding, high risk for bleeding complication (major intracranial surgery), or significant overt bleeding, discontinuation of P2Y 12 after 3 mo may be reasonable (COR IIB, LOE C-LD).If BMS or DES and good tolerance of DAPT and not high bleeding risk, continuing DAPT beyond the 1 or 6 month duration may be reasonable (COR IIb, LOE A).If DES, treat with DAPT, including a P2Y 12 inhibitor for ≥6 months (COR I, LOE B-R).If BMS, treat with DAPT, including a P2Y 12 inhibitor for ≥1 month (COR I, LOE A).If stable ischemic heart disease treated with PCI:.The dose of ASA 81 mg recommended in DAPT (COR I, LOE B-NR).Extended therapy with aspirin and clopidogrel after MI was explored in DAPT. The study reported that ticagrelor reduced the rate of death from vascular causes, MI, or stroke in patients who have an acute coronary syndrome as compared to clopidogrel.

#Timi trials trial#

It is important to note that patients in the trial were at a high risk of ischemic events and those with recent bleeding or requirement for oral anticoagulants were excluded.Īnother study on ticagrelor is the PLATO.

However, the risk of TIMI major and minor bleeding are significantly increased. The study showed that ticagrelor (90 mg or 60 mg, twice daily dose) significantly reduced the risk of cardiovascular death, MI, or stroke. Published 2015, the Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial randomized 21,162 patients who had prior MI 1-3 years earlier to receive ticagrelor (90 mg or 60 mg, twice daily) or placebo. Ticagrelor is a reversible P2Y 12 receptor antagonist which has been reported to be more effective and more rapid in inhibiting platelet aggregation as compared to clopidogrel. In patients who had prior MI 1-3 years earlier, ticagrelor (90 mg or 60 mg, twice daily) in combination with ASA significantly reduced the risk of cardiovascular death, MI, or stroke. S.In patients who had an MI in the prior 1-3 years, does ticagrelor+ASA reduce the risk of cardiovascular death, myocardial infarction, or stroke as compared to placebo? Palo Alto, California, United States, 94304 University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 Ĭentral Arkansas Veterans Health Care System

New, symptomatic ATE (inclusive of ischemic stroke, MI, or peripheral arterial thromboembolism) for up to 30 days after randomization as measured by hospital records.

New, symptomatic VTE (inclusive of DVT, PE, or other venous thrombosis) for up to 30 days after randomization as measured by hospital records.

The composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality as measured by hospital records.

The composite outcome of all-cause mortality and the EQ5D index score.

Samples will be collected at the time of enrollment and after the completion of 30 days of therapy The primary objective is to determine the most effective and safe antithrombotic strategy to prevent the composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality by 30 days following discharge from the hospital.īiobanking of samples for future biomarker and mechanistic studies will be available for centers able to participate and collect samples from eligible participants. For Stage 1 of this study, participants will be randomized to either prophylactic anticoagulation or matching placebo for 30 days, and then followed for an additional 60 days after the completion of treatment (total duration of follow-up, 90 days).

This study is an adaptive, prospective, randomized platform trial designed to compare the effectiveness and safety of antithrombotic therapy with no antithrombotic therapy after hospitalization for 48 hours or longer for COVID-19.

Why Should I Register and Submit Results?.